Profil
Alain Klapholz is the founder and currently holds the position of Chief Technical & Financial Officer at OptMed, Inc., a company he founded in 2007.
Mr. Klapholz completed his undergraduate degree at Yeshiva University in 1977 and obtained an MBA from The Leonard N Stern School of Business in 1979.
Aktive Positionen von Alain Klapholz
| Unternehmen | Position | Beginn |
|---|---|---|
OptMed, Inc.
 OptMed, Inc. Medical SpecialtiesHealth Technology OptMed, Inc. is a clinical-stage medical device company, which engages in the development and commercialization of surgical adhesives for the treatment of patients with external and internal wounds. The firm offers products under the brands of BondEase Topical Skin Adhesive and TearRepair Liquid Skin Protectant. Its proprietary technology platform is based on a chemistry called methylidene malonate (MM212), a biocompatible polymer originally designed for drug delivery which has been tested for biocompatibility and adhesive properties in topical and internal applications. The company was founded by Alain Klapholz in 2007 and is headquartered in New York, NY. | Gründer | 01.01.2007 |
Ausbildung von Alain Klapholz
| Yeshiva University | Undergraduate Degree |
| The Leonard N Stern School of Business | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
OptMed, Inc.
OptMed, Inc. Medical SpecialtiesHealth Technology OptMed, Inc. is a clinical-stage medical device company, which engages in the development and commercialization of surgical adhesives for the treatment of patients with external and internal wounds. The firm offers products under the brands of BondEase Topical Skin Adhesive and TearRepair Liquid Skin Protectant. Its proprietary technology platform is based on a chemistry called methylidene malonate (MM212), a biocompatible polymer originally designed for drug delivery which has been tested for biocompatibility and adhesive properties in topical and internal applications. The company was founded by Alain Klapholz in 2007 and is headquartered in New York, NY. | Health Technology |
